跳至主要内容
临床试验/jRCT2080222649
jRCT2080222649已完成3 期

Phase III clinical study of TY-0201 in patients with chronic atrial fibrillation -long-term study-

TOA EIYO LTD.1 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
TOA EIYO LTD.
入组人数
100
试验地点
1
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Multicenter, open-label study
主要目的
Treatment Purpose

入排标准

年龄范围
20age old over 至 80age old under(—)
性别
All

入选标准

  • (1) Patients with chronic (persistent or permanent) atrial fibrillation.
  • (2) Resting heart rate: >=80 bpm
  • (3) Outpatients

排除标准

  • (1) Patients with any of the following findings related to heart disease.
  • Acute coronary syndrome, coronary revascularization or variant angina within 6 months prior to informed consent.
  • Cardioversion or catheter ablation within 3 months prior to informed consent.
  • Heart rate control with a pacemaker, etc.
  • Severe arrhythmia, cardiogenic shock, heart failure, cardiomyopathy, myocarditis or reduced cardiac function, aortic valve or mitral valve with moderate or severe valve stenosis or valve regurgitation.
  • (2) Patients with a history of a cerebrovascular event (except for asymptomatic cerebrovascular events).
  • (3) Systolic blood pressure < 110 mmHg.
  • (4) Patients contraindicated for anticoagulation therapy.
  • (5) Patients with poor skin condition at the site of patch application or a history of clinically significant dermatitis caused by a topical agent, etc.

结局指标

主要结局

-

safety Adverse events and adverse drug reactions

次要结局

未报告次要终点

研究者

发起方
TOA EIYO LTD.

研究点 (1)

Loading locations...

相似试验